Dynavax Technologies stock (US2681581009): cash merger delivers Sanofi buyout at 15.50 USD per share

Dynavax Technologies is being acquired by Sanofi in an all?cash deal at 15.50 USD per share. What the completed merger means for former DVAX shareholders, the Hepatitis B vaccine franchise, and the company’s de?listing from US exchanges.

Dynavax Technologies is in the spotlight after the specialty vaccine maker was acquired by French pharma group Sanofi in a completed all?cash merger that values the company at 15.50 USD per share, according to a corporate actions update from Robinhood dated 2026 and Sanofi’s 2026 press release on the transaction completionRobinhood as of 2026Sanofi as of 2026.

The cash merger means that Dynavax Technologies shareholders receive a fixed consideration in cash per former DVAX share and the stock is being removed from regular trading on US exchanges, according to the Robinhood corporate actions tracker for 2026Robinhood as of 2026.

As of: 09.06.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Dynavax Technologies Corporation
• Sector/industry: Biotechnology / vaccines
• Headquarters/country: United States
• Core markets: Hepatitis B prevention and vaccine adjuvants
• Key revenue drivers: Hepatitis B vaccine franchise and CpG 1018 adjuvant partnerships
• Home exchange/listing venue: Formerly Nasdaq (ticker: DVAX)
• Trading currency: US dollar (USD)

Dynavax Technologies: core business model

Dynavax Technologies has historically focused on developing and commercializing vaccines and immune?modulating technologies, with a core competence in toll?like receptor 9 (TLR9) agonists and adjuvants used to enhance vaccine responses, according to the company’s long?standing product descriptions in prior investor materialsDynavax investor information as of 2025.

The company’s most prominent commercial product has been a Hepatitis B vaccine designed for adults, which incorporated its proprietary CpG 1018 adjuvant to provide higher seroprotection rates and a shortened dosing schedule versus earlier generation vaccines, as noted in earlier Dynavax communications and regulatory filings from the mid?2020sDynavax investor information as of 2025.

In addition to its own branded vaccine, Dynavax Technologies built a partnership model around CpG 1018 as an adjuvant for other pharmaceutical and biotech companies, aiming to support the development of new or improved vaccines for infectious diseases by contributing its immune?stimulating technology while partners advanced clinical programsDynavax investor information as of 2025.

The company’s business model therefore combined direct commercial revenues from its Hepatitis B vaccine franchise in the United States and selected other markets with collaboration and supply revenues from CpG 1018?based partnerships, a structure that appealed to larger pharma groups seeking specialized vaccine technology providersDynavax investor information as of 2025.

Main revenue and product drivers for Dynavax Technologies

Dynavax Technologies’ primary revenue driver in the years before the Sanofi transaction was its adult Hepatitis B vaccine franchise, marketed mainly in the US and targeting higher?risk populations and adults seeking more efficient immunization schedules, according to product discussions in historical company presentations and US market commentary from the early? to mid?2020sDynavax investor presentation as of 2024.

The vaccine’s differentiation rested on the CpG 1018 adjuvant, which activates innate immune pathways to boost antibody responses and allowed Dynavax Technologies to compete in a crowded Hepatitis B prevention market that included long?established brands from large pharmaceutical firmsDynavax investor presentation as of 2024.

Beyond Hepatitis B, CpG 1018 became an important strategic asset as partners explored its use in other adult and pandemic?preparedness vaccines, contributing adjuvant sales and development?related revenues that introduced a diversified, though more volatile, income stream tied to clinical and regulatory milestonesDynavax investor information as of 2024.

For US?based investors, Dynavax Technologies represented a focused vaccine specialist listed on Nasdaq in US dollars, with revenues and clinical collaborations connected to both domestic healthcare demand and global infectious?disease preparedness initiatives, as described in prior financial reports and sector analyses from the 2020sDynavax annual report as of 2024.

Industry trends and competitive position

The broader vaccine industry has seen continued consolidation as large pharmaceutical companies seek specialized technologies to enhance immunogenicity, broaden age indications and respond more quickly to emerging pathogens, a trend that has been highlighted in sector reviews and M&A reports for vaccine developers in the mid?2020sSanofi as of 2026.

By acquiring Dynavax Technologies, Sanofi is aiming to strengthen its position in the adult Hepatitis B market and augment its adjuvant capabilities, integrating CpG 1018 into a broader vaccine portfolio that spans influenza, COVID?19 legacy products and pediatric immunizations, as suggested by the strategic rationale described in Sanofi’s 2026 press release announcing the completion of the transactionSanofi as of 2026.

For the competitive landscape, Dynavax Technologies’ technology is expected to be deployed within Sanofi’s global distribution network, which could expand the geographic reach of CpG 1018?based vaccines beyond the markets Dynavax previously served independently, according to commentary in the same Sanofi communication from 2026Sanofi as of 2026.

Why Dynavax Technologies matters for US investors

Although Dynavax Technologies has been taken private within Sanofi via an all?cash merger, the transaction is still relevant for US investors because it illustrates the appetite of global pharmaceutical groups for US?listed vaccine specialists and the types of valuation levels that strategic buyers are willing to pay, as reflected by the 15.50 USD cash consideration reported in Robinhood’s corporate actions tracker for 2026Robinhood as of 2026.

The case of Dynavax Technologies also highlights how mid?cap biotech companies with a focused commercial product and a differentiated technology platform can transition from independent Nasdaq listings into being divisions of global pharma groups, changing the risk?reward profile for shareholders from long?term clinical and commercial uncertainty to a fixed?value cash exitRobinhood as of 2026.

For market participants tracking the US biotech sector, the transaction underscores ongoing consolidation trends and the importance of monitoring corporate actions announcements and exchange notices when holdings are subject to mergers, particularly when shares cease trading and are settled for cash following closingRobinhood as of 2026.

Conclusion

The completed all?cash acquisition of Dynavax Technologies by Sanofi at 15.50 USD per share closes a chapter for DVAX as an independent Nasdaq?listed vaccine specialist and shifts the story toward integration into a larger global pharmaceutical portfolio, according to Sanofi’s 2026 press release and corporate actions data from Robinhood for the same yearSanofi as of 2026Robinhood as of 2026.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.